1Van Bambekel F, Michotl JM, Van Eldere J, et al. Quinolones in 2005: an update. Clin Microbiol Infect,2005,11: 256-280. 被引量：1
2Andriole VT. The quinolones : past, present, and future. Clinic Infect Dis, 2005,41 Suppl 2 :S113-S119. 被引量：1
3Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother,2003,51 Suppl 1 : S13-S20. 被引量：1
4Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother,2003,51 Suppl 1 :S1-S11. 被引量：1
5Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician, 2002,65:455-464. 被引量：1
6Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother, 2002, 50 : 151-154. 被引量：1
7Ferrarn AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection,2005,33 : 106-114. 被引量：1
8Takagi H, Tanaka K, Tsuda H, et al. Clinical studies of garenoxaein. Int J Antimicrob Agents,2008,32:468-474. 被引量：1
9Okumura R, Hirata T, Onodera Y, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase Ⅳ: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimierob Chemother,2008 ,62 :98- 104. 被引量：1
10] Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med, 2005,165 : 1363-1369. 被引量：1
4Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153. 被引量：1
5Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545. 被引量：1
6Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301. 被引量：1
7Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754. 被引量：1
8Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408. 被引量：1
9Quale J,Landman D,Saurina G, et al. Manipulation of a hospital antimicrobial fomnulary to control an outbreak of vancomycin resistant enterococci. Clin Infect Dis, 1996,23 : 1020. 被引量：1
10Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149. 被引量：1
